45 results about "Cholesterol derivatives" patented technology

Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer, preferably hepatocellular carcinoma (HCC).

The invention specifically relates to a chloroquine cholesterol derivative, and a preparation method and application thereof, belonging to the field of the chemical pharmaceutical industry. The chloroquine cholesterol derivative provided by invention has a structure as shown in a formula I which is described in the specification. The invention also provides the preparation method and application of the chloroquine cholesterol derivative. The chloroquine cholesterol derivative provided by the invention can effectively inhibit the proliferation of rat fibroblasts and treat pulmonary fibrosis, exerts anti-inflammatory effect, and offers a novel option for preparation of anti-fibrotic, anti-inflammatory and anti-tumor drugs.

The invention discloses a cholesterol derivative, an O / W / O multi-phase gel emulsion prepared from the cholesterol derivative, and a method for preparing a porous silicon dioxide bulk material from the emulsion. The structural formula of the cholesterol derivative is as shown in the description, wherein n is an integer of 6 to 12, and R represents a C1-C4 alkyl group. The O / W / O multi-phase gel emulsion is prepared according to a one-step method by taking the cholesterol derivative as a sing surfactant and taking a silanization reagent as an oil-phase material, and is high in stability, stable to acid and alkali, uniform in droplet distribution, and high in water-phase content which is 80 to 97 percent of the total volume. The porous silicon dioxide bulk material is prepared by taking the O / W / O multi-phase gel emulsion as a template at an ammonia gas atmosphere. The method is simple and low in cost; the prepared silicon dioxide bulk material is low in density, and has rich hierarchical porous structures which are regular and high in permeability; moreover, the porous silicon dioxide bulk material is large in surface area, high in heat stability, adjustable in hydrophilicity and hydrophobicity, and excellent in water or oil adsorption property.

The invention belongs to the field of organic synthesis, and discloses a pillararene-based liquid crystal material and a preparation method thereof. A pillar[5]arene‑cholesterol derivative 1 bridged with a rigid Schiff base spacer was designed and synthesized via aldolamine condensation. Then, [3] pseudorotaxanes were obtained through the host-guest interaction between the pillar [5] arene-cholesterol derivative 1 and the guest 2 containing a dinitrile group. Since the Schiff base group can interact with Cu 2+ Coordinated, quasi[3]rotaxanes can be further cross-linked to obtain a three-dimensional supramolecular polymer network. The preparation method of the supramolecular network polymer is simple, the cost is low, and it has liquid crystal behavior, which provides a new method for the construction of pillar arene-based liquid crystal materials.